...Absolutely. Thanks, David. It's nice to be here with you today. You're right about Alnylam as a platform company. And I think it's sort of the truest definition of the word, it's a platform company. The company was founded in 2002 and has been pioneering a new class of medicine called RNAi therapeutics. And that's based on Nobel prize winning science that allows the company to essentially silence any gene in the genome and turn off the production of disease-causing proteins. And the company has made a huge amount of progress here relatively recently in terms of of that platform now starting to bear fruit in the way of approved drugs. And you mentioned it that in the last 2 years roughly, the company has now had 3 approvals, where we've got 3 drugs in the market, the first being ONPATTRO, for hereditary ATTR amyloidosis for patients with polyneuropathy. And that's a drug that in the most recent quarter delivered $82.5 million in revenue, and we've got more than 1,150 patients on that drug...
